Publikationen:

Differently regulated miRNAs as prognostic biomarkers in the blood of primary CNS lymphoma patients. Roth P, Keller A, Hoheisel JD, Codo P, Bauer AS, Backes C, Leidnger P, Meese E, Thiel E, Korfel A, Weller M. Eur J Cancer 2015;51: 382 – 390

Prognostic impact of intraocular involvement in primary CNS lymphoma: experience from the G-PCNSL-SG1 trial. Kreher S, Strehlow F, Martus P, Hertenstein B, Röth A, Birnbaum T, Griesinger F, Rauch M, Kanz L, Thiel E, Weller M, Korfel A. Ann Hematol. 2015;94: 409 – 414

Pathogenesis and management of primary CNS lymphoma. Roth P, Korfel A, Martus P, Weller M. Expert Rev Anticancer Ther. 2012;12: 623 – 633

Prognostic impact of meningeal dissemination in primary CNS lymphoma (PCNSL): experience fron the G-PCNSL-SG1 trial. Korfel A, Weller M, Martus P, Roth P, Klasen HA, Roeth A, Rauch M, Hertenstein B, Fischer T, Hundsberger T, Leithäuser M, Birnbaum T, Kirchen H, Mergenthaler HG, Schubert J, Berdel W, Birkmann J, Hummel M, Thiel E, Fischer L. Ann Oncol. 2012;23: 2374 – 2380

Surgery of primary CNS lymphoma? Challenging a paradigm. Weller M, Martus P, Roth P, Thiel E, Korfel A, German PCNSL Group. Neuro Oncol. 2012;14: 1481 – 1484

Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1. Roth P, Martus P, Kiewe P, Möhle R, Klasen H, Rauch M, Röth A, Kaun S, Thiel E, Korfel A, Weller M. Neurology 2012;79: 890 – 896

High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, Röth A, Hertenstein B, von Toll T, Hundsberger T, Mergenthaler HG, Leithäuser M, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, Nägele T, Pietsch T, Bamberg M, Weller M. Lancet Oncol. 2010;11: 1036 – 1047